Tessera Therapeutics Awarded up to $41.3 Million from ARPA-H to Advance In Vivo CAR-T Therapies
Award will support development of a single dose in vivo chimeric antigen receptor T cell (CAR-T) therapy to retrain immune cells directly within the body to fight cancer and autoimmune diseases using Tessera's Gene WritingTM and delivery platforms SOMERVILLE, Mass, Oct. 08, 2025 (GLOBE NEWSWIRE) — Tessera Therapeutics, a biotechnology company pioneering a new approach […]